Academic Journal
Systematic literature review and network meta-analysis of therapies for psoriatic arthritis on patient-reported outcomes
| العنوان: | Systematic literature review and network meta-analysis of therapies for psoriatic arthritis on patient-reported outcomes |
|---|---|
| المؤلفون: | Nash, Peter, Dutz, Jan P, Peterson, Steve, Patel, Barkha P, Eaton, Kiefer, Shawi, May, Zazzetti, Federico, Wei, James Cheng-Chung |
| بيانات النشر: | BMJ Publishing Group Ltd |
| سنة النشر: | 2023 |
| المجموعة: | HighWire Press (Stanford University) |
| مصطلحات موضوعية: | Patient-centred medicine |
| الوصف: | Objectives Head-to-head clinical trials are common in psoriasis, but scarce in psoriatic arthritis (PsA), making treatment comparisons between therapeutic classes difficult. This study describes the relative effectiveness of targeted synthetic (ts) and biologic (b) disease-modifying antirheumatic drugs (DMARDs) on patient-reported outcomes (PROs) through network meta-analysis (NMA). Design A systematic literature review (SLR) was conducted in January 2020. Bayesian NMAs were conducted to compare treatments on Health Assessment Questionnaire Disability Index (HAQ-DI) and 36-item Short Form (SF-36) Health Survey including Mental Component Summary (MCS) and Physical Component Summary (PCS) scores. Data sources Ovid MEDLINE (including Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily),Embase and Cochrane Central Register of Controlled Trials. Eligibility criteria Phase III randomised controlled trials (RCTs) evaluating patients with PsA receiving tsDMARDS, bDMARDs or placebo were included in the SLR; there was no restriction on outcomes. Data extraction and synthesis Two independent researchers reviewed all citations. Data for studies meeting all inclusion criteria were extracted into a standardised Excel-based form by one reviewer and validated by a second reviewer. A third reviewer was consulted to resolve any discrepancies, as necessary. Risk of bias was assessed using the The National Institute for Health and Care Excellence clinical effectiveness quality assessment checklist. Results In total, 26 RCTs were included. For HAQ-DI, SF-36 PCS and SF-36 MCS scores, intravenous tumour necrosis factor (TNF) alpha inhibitors generally ranked higher than most other classes of therapies available to treat patients with PsA. For almost all outcomes, several interleukin (IL)-23, IL-17A, subcutaneous TNF and IL-12/23 agents offered comparable improvement, while cytotoxic T-lymphocyte-associated antigen 4, phosphodiesterase-4 and Janus kinase inhibitors often had the lowest efficacy. Conclusions ... |
| نوع الوثيقة: | text |
| وصف الملف: | text/html |
| اللغة: | English |
| Relation: | http://bmjopen.bmj.com/cgi/content/short/13/11/e062306; http://dx.doi.org/10.1136/bmjopen-2022-062306 |
| DOI: | 10.1136/bmjopen-2022-062306 |
| الاتاحة: | http://bmjopen.bmj.com/cgi/content/short/13/11/e062306 https://doi.org/10.1136/bmjopen-2022-062306 |
| Rights: | Copyright (C) 2023, British Medical Journal Publishing Group |
| رقم الانضمام: | edsbas.80A58C55 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1136/bmjopen-2022-062306 |
|---|